Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /PRNewswire/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent ...

Goldman Sachs writes, “Overall, we see merit to Regeneron’s approach to improve the quality of weight loss (noting up to 40% of weight loss from incretin-based therapies is due to decreases in ...

(Reuters) - A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few ...

With the FDA signing off on high-dose Eylea, Regeneron and Bayer set to take on Roche’s Vabysmo in a battle for the massive eye disease market.